XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.
XDx is a molecular diagnostics company based in Brisbane, California, funded by Kleiner Perkins and other top tier venture capitalists. Setting the stage for a new era in personalized medicine, XDx was one of the first companies to develop and commercialize practical applications built on insights from the Human Genome Project. The company offers a method for noninvasively monitoring the immune system by measuring gene expression in a patient's peripheral blood. Our current AlloMap product is a test used to help in the management of heart transplant patients. Future applications of the XDx technology offer the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering, immune-mediated diseases. AlloMap has been used in nearly 100 centers in the US, and 30,000 commercial tests have been run in our lab.
Our culture is based on a belief in pioneering and innovation, integrity, people development, community, and balance in our day to day lives. This is a place where you can make a difference, learn new skills, and work with outstanding people.
Link up your social media account to automatically promote the positions at XDx, Inc..
Get a job alert every time XDx, Inc. posts a job.
XDx, Inc. does not have any jobs posted at this time.